From Bench-to-Bedside: A Review of Clinical Trials in Drug Discovery and Development

arXiv:2412.09378 · cs.CY, cs.CL · Submitted 2024-12-12 · Read on arXiv

cs.CY, cs.CL

Submitted: 2024-12-12

Updated: 2026-09-11

Comments: 18 pages. Published version. Revised to match the version of record; title, abstract, and text updated. Journal reference and DOI added

Journal ref: BIO Integration 7(1) (2026)

DOI: 10.15212/bioi-2025-0198

License: http://creativecommons.org/licenses/by/4.0/

The gist: Clinical trials bridge basic research and clinical application, serving as essential steps in drug development.

Terminology

Abstract

Clinical trials bridge basic research and clinical application, serving as essential steps in drug development. This review examines clinical trial phases (Phase I [safety assessment], Phase II [efficacy evaluation], Phase III [large-scale validation], and Phase IV [post-marketing surveillance]), highlighting the distinct characteristics and interconnections. Major challenges are identified, including ethical compliance, participant recruitment, and ensuring diversity and representativeness in trial populations, while proposing evidence-based mitigation strategies. To address these challenges, innovative technologies, such as artificial intelligence, big data analytics, and digital health tools, are transforming trial design and implementation, enhancing efficiency and data quality. Looking forward, the review explores how emerging therapies, including gene therapy and immunotherapy, are reshaping trial design requirements and emphasizes the growing importance of regulatory harmonization and global collaboration. Clinical trials remain central to advancing innovative drug development and improving patient outcomes.

Related papers